
BMS says Phase III Opdivo head and neck cancer trial stopped early
pharmafile | January 28, 2016 | News story | Medical Communications, Research and Development |
Bristol Myers Squibb has announced a Phase III study of Opdivo (nivolumab) in head and neck cancer patients was stopped early after meeting its primary endpoint of overall survival.
Independent assessors concluded Opdivo patients achieved greater overall survival than the placebo arm control group in the trial. BMS said it will share the data with health authorities soon as it seek to get the drug approved in this new indication: specifically recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck.
“With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options,” says Michael Giordano, senior vice president, head of Oncology Development, Bristol-Myers Squibb. “We look forward to continuing to advance the Opdivo clinical development program in hard-to-treat cancers, such as head and neck cancer.”
Joel Levy






